SARS-CoV-2 nsp14-IN-2_product_DataBase

Bioactivity	SARS-CoV-2 nsp14-IN-2 is a potent SARS-CoV-2 Nsp14 methyltransferase inhibitor with an IC50 value of 0.093 µM. SARS-CoV-2 nsp14-IN-2 shows antiviral activity. SARS-CoV-2 nsp14-IN-2 shows plasma and liver S9 stability. SARS-CoV-2 nsp14-IN-2 has the potential for the research of COVID-19[1].
Target	IC50: 0.093 µM (SARS-CoV-2 Nsp14 methyltransferase).
Invitro	SARS-CoV-2 nsp14-IN-2 (compound 10) (0-100 µM) shows antiviral activity with an EC50 value of 0.72 µM and CC50 value of >100 µM[1].SARS-CoV-2 nsp14-IN-2 (24 h) shows plasma stability with t1/2s of >24, >24 h for human and mouse, respectively[1].SARS-CoV-2 nsp14-IN-2 (45 min) shows liver S9 stability with t1/2 values of 842 min and >45 min in Phase I and phase II in human liver, respectively; and t1/2 values of 28.9 min and >45 min in Phase I and phase II in mouse liver, respectively[1].
Name	SARS-CoV-2 nsp14-IN-2
CAS	2816165-16-7
Formula	C21H21N5O5S
Molar Mass	455.49
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Eunkyung Jung， et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. 2022.

PeptideDB